MELANOMA

This early-phase trial tests a custom-made RNA vaccine designed to help the immune system recognize and attack tumors in people with advanced melanoma or soft tissue sarcoma whose cancer has worsened despite standard immunotherapy. Up to 18 adults will receive three doses of the …

This early-stage study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can improve treatment for advanced melanoma. About 94 adults with stage III or IV melanoma will participate. The goal is to find the safest dose an…

This study looks at whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug treatments can better control brain tumors in people with melanoma or non-small cell lung cancer that has spread to the brain. About 180 participants with newly diagnosed, …

This study tests whether combining two drugs, axitinib and ipilimumab, can shrink or control advanced melanoma that has not responded to standard immunotherapy. About 25 adults with advanced melanoma will receive the combination. The goal is to see how many patients' tumors shrin…

This study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…

This study tests a new two-drug combination (fianlimab and cemiplimab) against an already approved combination (relatlimab and nivolumab, sold as Opdualag) in people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if the new combo is saf…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 adults will receive treatment based on their tumor's unique markers. The goal is to see if this approach leads to a major or complete response in…

This early-phase study tests a new drug called AZD6750, which is designed to guide the immune system to attack cancer cells. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will check …

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety. About 10 participants will receive one of two dose lev…

This study tests a new treatment for several types of cancer that have a specific marker called CD70. Researchers take a patient's own white blood cells, modify their genes in the lab to help them recognize and attack CD70-positive cancer cells, and then return them to the patien…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapies. OBX-115 uses a patient's own tumor-fighting immune cells (TILs) that have been modified to produc…

This study tests whether adding the drug tarlatamab to standard radiation is safe and effective for cancers that have a protein called DLL3. About 30 adults with cancers like melanoma, lung cancer, or glioblastoma will receive the combination. The goal is to find the best timing …

This early-stage study tests a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goal is to check safety and find the right dose. About 150 participants will take part in this first-in-human tria…

This early-phase trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for advanced uveal melanoma, undifferentiated pleomorphic sarcoma, or dedifferentiated liposarcoma. About 30 participants will have their tumor removed, have …

This trial tests whether a combination of two drugs, vemurafenib and cobimetinib, can shrink or control rare cancers that have a specific BRAF V600 mutation. The drugs are already approved for melanoma, and researchers want to see if they help people with other cancer types, like…

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people whose non-small cell lung cancer, melanoma, or kidney cancer has been surgically removed. The goal is to see how the body processes HLX17 compared to Keytruda, and to check fo…

This study tests whether adding a personalized cell therapy (lifileucel, made from a patient's own tumor-fighting immune cells) to the standard immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. A…

This study tests a new drug called NUC-7738 in people with advanced solid tumours or lymphoma that have not responded to other treatments. The goal is to find the safest dose and see if it can shrink tumours, either alone or combined with another drug (pembrolizumab). About 135 a…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to an existing immunotherapy (atezolizumab) can help control several advanced solid tumors, including pancreatic, lung, bladder, and triple-negative breast cancer. About 247 adults with t…

This study tests a new treatment using a patient's own immune cells, modified to target two proteins (NG2 and DLL3) found on melanoma cells. It is for people with advanced melanoma that has come back or not responded to standard therapy. The goal is to see if this approach is saf…

This study tests a new way to treat advanced melanoma by boosting a patient's own immune cells (TIL) with a molecule called CD40L. After removing a tumor, the cells are grown in a lab, strengthened, and given back to the patient along with chemotherapy and short-term IL-2. The go…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs can shrink tumors. About 240 a…

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to check safety and side effects. About 33 participants will be enrolled to see if this comb…

This early-stage trial tests a new drug called BI-1808, alone or with pembrolizumab, in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see if…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This study tests an experimental drug called N17350 for adults with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers aim to find the safest and most effective dos…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…

This study tests whether using a PET scan to guide radiation therapy can better control lung cancer, melanoma, or kidney cancer that has started growing again in up to 5 spots. About 32 adults will receive either standard radiation or a PET-adapted version that delivers a higher …

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with advanced melanoma that has worsened after standard treatments. The goal is to see if this combo can shrink tumors. About 60 adults with unresectable stage III or IV melanoma will tak…

This early-stage study tests a new drug called BI 3810944 in adults with advanced solid tumors or melanoma who have run out of treatment options. The goal is to find safe doses and see if the drug can shrink tumors. Participants receive the drug every three weeks, with more frequ…

This study tests a new combination of immune cells (CAR T cells, CTLs, and DC vaccines) to fight advanced melanoma that has spread or come back after standard treatment. About 30 adults aged 18-75 will receive these cells to see if the approach is safe and shrinks tumors. The goa…

This study tests a combination of two experimental drugs, HX009 and IN10018, with or without standard chemotherapy, in people with advanced solid tumors like bile duct cancer and melanoma that have not responded to prior treatments. The goal is to find the best dose and see if th…

This study follows up to 100 people with cancers like melanoma, lung cancer, or rare tumors who are already benefiting from treatment with dabrafenib and/or trametinib. The goal is to monitor long-term safety and side effects while patients continue their medication. Participants…

This study tests a drug called pembrolizumab in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, come back, or not responded to treatment. The drug helps the immune system fight cancer. The goal is to see if it can shrink or el…

This study tests whether combining two drugs—cyclophosphamide and pembrolizumab—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 14 adults with stage III or IV melanoma will receive the combination. The goal is to see if …

This study looks at how well the drug T-DXd works for people with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. About 100 adults in the US will be followed to see if their tumors shrink or stop growing. The goal is to u…

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus liver radiation. The goal is to s…

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB), high microsatellite instability (MSI), or a specific DNA repair defect (CMMRD). About 30 adults, teens, and children will receive the…

This program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…

This early-stage study tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose. About 450 adults with cancers like lung, …

This study tests whether adding the arthritis drug sarilumab to a three-drug immunotherapy cocktail can make treatment safer and more effective for people with advanced (stage III or IV) melanoma that cannot be removed by surgery. About 105 participants will receive the combinati…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 170 adults aged 18 to 72 with skin melanoma that has spread will take part. Participants rec…

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This study tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to attack the cancer. About 98 participants wi…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take part in this early-phase trial.

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby organs. Research…

This study tests a personalized cancer vaccine made from patients' own tumor cells. The goal is to train the immune system to fight metastatic cancers like melanoma, breast, lung, and colorectal cancer. Participants receive eight injections over 16 weeks. The study is for adults …

This early-phase trial tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway and have stopped responding to standard treatments. The study aims to find a safe dose and check for early signs of tumor s…

This study tests a drug called entrectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change (ROS1 fusion). About 30 adults and children with these rare tumors will receive the drug. Researchers will measure if tumors shrink …

This early-phase study tests a treatment called RP1, a modified herpes virus, injected directly into melanoma tumors. The goal is to see if it can kill cancer cells and reduce the risk of the cancer spreading to nearby lymph nodes. The study involves 25 adults with thick or high-…

This study tests a new oral drug, IPN01194, in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find the right dose and check if the drug is safe and can shrink tumors. Ab…

This early-stage trial tests a personalized cell therapy for children and young adults (up to age 21) with solid tumors that have come back or not responded to standard treatment. Doctors take the patient's own immune cells, modify them to recognize a protein called B7-H3 on tumo…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to shrink tu…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests an experimental drug called TRK-950, alone or with another drug (nivolumab), in people with advanced solid tumors or melanoma that have not responded to standard treatments. The goal is to check safety, find the right dose, and see if the drug can shrink tumors. …

This early-stage study tests two drugs, ulixertinib and palbociclib, together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find the safest dose and check for side effects. About 45 adults whose cancer has not respond…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This study looks at whether giving radiation therapy to the lymph nodes, along with standard immunotherapy, can lower the chance of melanoma coming back in patients with high-risk features. About 168 adults with melanoma that has spread to a sentinel lymph node will receive radia…

This study looks at whether adding a prebiotic-rich diet to standard immunotherapy (ipilimumab and nivolumab) can improve the immune response in people with melanoma that can be surgically removed. About 35 adults with stage III or IV melanoma will follow the diet and take the dr…

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard treatments. The drug is given both into a vein and directly into the tumor to see if it can shrink or contro…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help keep advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or with LND101. The goa…

This early-phase trial tests a new treatment for people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line therapy. The treatment involves taking a patient's own immune cells, modifying them in the lab to better recognize and atta…

This study is for people with stage III melanoma that has spread to just one lymph node. Doctors want to see if removing only that cancerous node can prevent the cancer from coming back in the same area, compared to removing more nodes. The trial will also track side effects like…

This study tests whether a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) can shrink or stabilize melanoma tumors that have spread to the brain. About 60 adults with melanoma brain metastases will receive the drugs intravenously. The main goal is…

This study tests whether giving two doses of immunotherapy drugs (ipilimumab and nivolumab) before surgery can help shrink tumors in people with melanoma that has come back after previous treatment. About 25 adults with advanced but removable melanoma will receive the drugs, then…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study is testing a new type of PET scan that uses a special tracer to find cancers like pancreatic, breast, lung, and others. The goal is to see if this scan can better detect and stage tumors compared to standard scans. About 26 adults with suspected or confirmed cancer, pl…

This study tests whether a special ultrasound with contrast dye can find the first lymph node where cancer might spread, instead of using the standard radioactive method. About 91 adults with melanoma, breast cancer, or head & neck cancer will take part. If it works, it could mak…

This study is testing a new platform that uses advanced genetic and functional tests to better understand tumors from 300 people with various high-risk cancers, including leukemia, myeloma, and pancreatic cancer. The goal is to see if this detailed analysis can change the recomme…

This study tests whether a preventive lymphovenous bypass—a rerouting of lymphatic fluid—can stop lymphedema (arm swelling) from developing after lymph node removal. About 252 adults with advanced breast cancer or melanoma will receive the bypass before their scheduled lymph node…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better than standard radiation and whether it helps the immune system attack cancer cells. Abo…

This study tests a telemedicine program called FOCUS for people with advanced cancer. The program uses counseling techniques to help manage common symptoms like trouble sleeping, worry, tiredness, and low mood. Researchers will enroll 120 adults with advanced lung, breast, prosta…

This study tests whether a virtual mind-body program called IM@Home can reduce fatigue and improve quality of life for adults with head and neck, thoracic, gynecologic, or other cancers who are receiving treatments like chemotherapy or radiation. About 480 participants will be en…

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely reduce diarrhea and colon inflammation caused by immune-checkpoint inhibitors in people with genitourinary and other cancers. About 40 participants will receive FMT and be monitored for side ef…

This study tests whether giving cancer treatment at home is preferred over going to a clinic. It involves 27 adults with various cancers in the Florida Panhandle. The goal is to see if home care improves patient satisfaction and is safe.

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease). The tool helps patients understand immune checkpoint inhibitor drugs and their possible side effects. Researchers wil…

This study is testing a program called MyCarePulse and ASCENT to help cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either receive the program or standard care. Researchers will measure changes in food security, di…

This study looks at how effective first-line immunotherapy is for people with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. Researchers will track tumor shrinkage, time to progression, and side effects, and analyze blood, stool, and body fluids t…

This study uses a 10-minute online questionnaire to understand how the COVID-19 pandemic impacted the well-being, stress, finances, and social life of people with melanoma. Researchers will look at factors like social support and coping skills that may help buffer negative effect…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can find cancer early after treatment. Researchers will follow about 100 people with different solid tumors, plus healthy volunteers, to see if the test helps predict when cancer comes back. …

This study collects and stores tissue samples from 3,000 people with melanoma to learn about the biological changes that cause and spread the disease. The goal is to help doctors choose the best treatments for each patient by analyzing the genetic details of their cancer. Partici…

This study follows 2000 adults with newly diagnosed cancers (breast, colorectal, lung, melanoma, or lymphoma) who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps reduce symptoms like pain, nausea, or fatigue, and al…

This study collects blood and leftover tissue samples from 9,600 adults with different types of cancer. Researchers will use these samples to develop and improve tests that detect cancer DNA in the blood, which may help monitor for cancer return or how well treatment is working. …

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study tracks fertility changes in 80 melanoma patients (women 18-37, men 18-45) before, during, and after treatment with anti-PD-1 or targeted therapy. Researchers measure hormone levels in women and sperm quality in men to understand how these treatments impact the ability …

This study looks at how genes and environment affect melanoma risk in people with a personal or family history of the disease. Up to 3,000 participants will fill out questionnaires, give blood or cheek cell samples, and may have skin exams and biopsies. The goal is to find genes …

This study looks at how a standard melanoma immunotherapy (anti-PD1) changes the appearance and biology of atypical moles in people with stage IIB-IIIC melanoma. About 30 participants with at least two atypical moles will be followed to see if the treatment alters mole size, colo…

This study follows 350 adults with stage III-IV melanoma for two years after diagnosis to learn how their quality of life and mental health change. Researchers will also test if a type of talk therapy called cognitive behavioral therapy can help reduce cancer-related stress. The …

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer. The samples will be stored and used in future research to better understand how cancers grow and respond to treatment. No new treatments are being tested; the goal…

This study is collecting blood, tissue, urine, and saliva from 7,000 people with many types of cancer to look for tiny bits of cancer DNA left after treatment. The goal is to find out if this DNA test can spot remaining cancer early and help doctors decide on next treatments. Par…

This study is testing a new tool that predicts whether immunotherapy will work for people with melanoma and other skin cancers. Researchers will collect tumor tissue, blood, and stool samples from 1,000 participants and compare the tool's predictions to actual treatment outcomes.…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study is testing a mobile app called Vigilant to help monitor side effects in 100 people with skin cancer or melanoma who are starting a specific type of immunotherapy. Participants will use the app to report symptoms, and researchers will see how well it works for tracking …

This study looks at the genetic information inside tumor samples from children and teens with melanoma or related skin growths. Researchers want to learn what makes these rare cancers different from adult melanomas. The study does not test any new treatments, but it may help doct…

This study is for people with advanced cancers who are taking targeted treatments for months or years. Researchers will interview 75 participants to understand their experiences and needs. The goal is to find better ways to support patients living with chronic cancer treatments.

This study screens up to 7,000 adults with cancers like melanoma, lung, or colorectal cancer to see if they qualify for experimental treatments developed by the National Cancer Institute's Surgery Branch. These treatments involve taking a patient's own immune cells, growing them …

This study aims to see if watching a video before genetic testing helps people with certain cancers better understand their hereditary cancer risk. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Resear…

This study looks at whether giving young adults (ages 18-39) with cancer the option to choose how they report their symptoms and well-being leads to better data. About 400 participants will be randomly assigned to either a fixed set of questions or a choice of questions. The goal…

This study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years.

This study analyzes tumor tissue from up to 12,000 cancer patients to identify gene mutations. The goal is to match each patient with a clinical trial or therapy that targets their specific cancer type. Researchers will also build a database of mutations to improve future cancer …

This study tests whether a natural compound called urolithin A can improve the immune response in people with solid tumors (like lung cancer or melanoma) who are starting standard immunotherapy. About 45 adults will be randomly assigned to take either urolithin A or a placebo alo…

This study tests a digital tool called mySmartSkin to help melanoma survivors do better skin self-exams. About 385 people who had melanoma will use the app and report how thoroughly they check their skin. The goal is to see if the app helps catch new or returning melanomas earlie…

This study collects blood and tumor samples from 1,000 people with melanoma and healthy volunteers. Researchers want to learn more about what causes melanoma and how tumors behave. The samples will be stored for future research that could lead to better ways to diagnose or treat …

This study looks at whether combining PET/CT scans with a special blood test (ctDNA) can help doctors predict which patients with advanced melanoma will respond to immunotherapy and who might have side effects. About 24 adults with stage III or IV melanoma will be followed for ab…

This study tracks 270 women under 40 who have had melanoma surgery and are now taking newer drugs (immunotherapy or targeted therapy) to prevent the cancer from coming back. Researchers want to see if these treatments harm the ovaries by measuring a hormone called AMH before and …

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter tumor cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults with melanoma before and after treatment to …

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…